At BioEquity 2019, Spanish Bioindustry Association ASEBIO has given a sneak peek into its 2018 Annual Report, that each year describes the news and trends from the Spanish Biotech Sector.
Chiesi Farmaceutici has licenced commercialiation rights for LHON treatment Raxone (idebenone) from Santhera Pharmaceuticals for CHF50m (€44m) in cash plus sales milestones.
https://european-biotechnology.com/wp-content/uploads/2024/04/EUministerCRISPR_123rf_Andrii_Panchyk_110478118_s.jpg611783Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2019-05-22 10:25:392019-05-22 10:25:39EU ministers set to exclude CRISPR crops from GMO legislation
https://european-biotechnology.com/wp-content/uploads/2024/04/eb_2019_Mogrify_CBO_Dr_Karin_Schmitt.JPG500500h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2019-05-20 16:34:332019-05-20 16:34:33Mogrify appoints new CBO and COO
Researchers at German regulatory authority Paul-Ehrlich Institute (PEI) have patented a method to accurately forecast biotech-based protein synthesis in host cells.
In an oversubscribed Series B round led by LSP, Paris-based DNA Script raised US$38.5. Bpifrance and existing investors Illumina Ventures, M. Ventures, Sofinnova Partners, Kurma Partners and Idinvest Partners contributed.
https://european-biotechnology.com/wp-content/uploads/2024/04/Bildschirmfoto_2019-05-16_um_15.31.40.png454775Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2019-05-17 06:22:002019-05-17 06:22:00DNA Script raises US$38.5m in Series B round
Although the Swiss biotech sector continues to grow and the annual Swiss Biotech Day is as sought-after as never before, panelists and attendees remain cautious with their predictions. A reoccurring theme at the event in Basel was the plea for change.
There is a growing demand for more patient-centric drug delivery and improved health-care cost management via self-administration and smart devices. The global drug device combination market is projected to reach nearly US$140m by 2025. It’s where the two different worlds of pharmaceutical (GMP) and standardised medical devices collide.Each needs to learn from the other in order to facilitate the regulation process in Europe.
https://european-biotechnology.com/wp-content/uploads/2024/04/eb_2019_inhaler.png5631000Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2019-05-16 14:06:002024-04-02 16:20:47A grey zone in regulation
Researchers from Universities Nijmegen and Naples have presented a retinal AAV-based gene therapy delivery system that can express huge genetic elements by assembling protein fragments from several vectors.
Healthy figures from Spain
Latest NewsAt BioEquity 2019, Spanish Bioindustry Association ASEBIO has given a sneak peek into its 2018 Annual Report, that each year describes the news and trends from the Spanish Biotech Sector.
Chiesi acquires ex-US Raxone marketing rights
Latest NewsChiesi Farmaceutici has licenced commercialiation rights for LHON treatment Raxone (idebenone) from Santhera Pharmaceuticals for CHF50m (€44m) in cash plus sales milestones.
EU ministers set to exclude CRISPR crops from GMO legislation
Latest NewsEU agriculture ministers want to exclude crops created by targeted mutation methods from EU GMO legislation.
Evotec acquires CDMO Just Biotherapeutics in US$90m deal
Latest NewsMogrify appoints new CBO and COO
AppointmentsMogrify appoints 15 new staff including, Dr Karin Schmitt as Chief Business Officer and Joe Foster as Chief Operating Officer
AI improves protein manufacture
Latest NewsResearchers at German regulatory authority Paul-Ehrlich Institute (PEI) have patented a method to accurately forecast biotech-based protein synthesis in host cells.
DNA Script raises US$38.5m in Series B round
Latest NewsIn an oversubscribed Series B round led by LSP, Paris-based DNA Script raised US$38.5. Bpifrance and existing investors Illumina Ventures, M. Ventures, Sofinnova Partners, Kurma Partners and Idinvest Partners contributed.
Hedging success
Latest NewsAlthough the Swiss biotech sector continues to grow and the annual Swiss Biotech Day is as sought-after as never before, panelists and attendees remain cautious with their predictions. A reoccurring theme at the event in Basel was the plea for change.
A grey zone in regulation
BackgroundThere is a growing demand for more patient-centric drug delivery and improved health-care cost management via self-administration and smart devices. The global drug device combination market is projected to reach nearly US$140m by 2025. It’s where the two different worlds of pharmaceutical (GMP) and standardised medical devices collide.Each needs to learn from the other in order to facilitate the regulation process in Europe.
Dutch-Italian team improves retinal gene therapy
Latest NewsResearchers from Universities Nijmegen and Naples have presented a retinal AAV-based gene therapy delivery system that can express huge genetic elements by assembling protein fragments from several vectors.